Boston Scientific Corporation (BSX)
Automate Your Wheel Strategy on BSX
With Tiblio's Option Bot, you can configure your own wheel strategy including BSX - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol BSX
- Rev/Share 13.0593
- Book/Share 15.9479
- PB 5.8027
- Debt/Equity 0.5149
- CurrentRatio 1.5081
- ROIC 0.0754
- MktCap 135874274809.0
- FreeCF/Share 2.5477
- PFCF 35.9932
- PE 48.692
- Debt/Assets 0.2821
- DivYield 0
- ROE 0.1242
- Rating B
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 4
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | BSX | Erste Group | Buy | Hold | -- | -- | Oct. 3, 2025 |
| Upgrade | BSX | Oppenheimer | Perform | Outperform | -- | $125 | Sept. 8, 2025 |
| Initiation | BSX | Leerink Partners | -- | Outperform | -- | $118 | June 16, 2025 |
| Upgrade | BSX | Needham | Hold | Buy | -- | $113 | April 16, 2025 |
| Upgrade | BSX | Deutsche Bank | Hold | Buy | -- | $108 | Jan. 10, 2025 |
| Downgrade | BSX | Needham | Buy | Hold | -- | -- | Oct. 18, 2024 |
News
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Published: February 04, 2026 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (BSX) Q4 2025 Earnings Call Transcript
Read More
BSX Stock Dips in Premarket Trading Despite Q4 Earnings, Revenue Beat
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
BSX beats Q4 EPS and revenue estimates and lifts margins, but shares slide 9.1% in pre-market as investors weigh outlook and guidance.
Read More
Boston Scientific (BSX) Reports Q4 Earnings: What Key Metrics Have to Say
Published: February 04, 2026 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Boston Scientific (BSX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Boston Scientific Profit, Sales Rise but Issues Soft Guidance
Published: February 04, 2026 by: WSJ
Sentiment: Neutral
Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry (Revised)
Published: February 03, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: RAPT Therapeutics, Inc. (Nasdaq – RAPT), Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), FONAR Corporation (Nasdaq - FONR)
Published: February 02, 2026 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Read More
4 Medical Product Stocks to Watch From a Challenging Industry
Published: February 02, 2026 by: Zacks Investment Research
Sentiment: Negative
The Zacks Medical products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. BSX, RMD, PAHC and BLFS reflect the favorable fundamentals.
Read More
Boston Scientific (BSX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Published: January 30, 2026 by: Zacks Investment Research
Sentiment: Positive
Beyond analysts' top-and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2025.
Read More
Artisan Global Opportunities Fund Q4 2025 Portfolio Update
Published: January 29, 2026 by: Seeking Alpha
Sentiment: Neutral
Among our top contributors in Q4 were Argenx, Lam Research and Insmed. Among our biggest detractors in Q4 were Oracle, Netflix and BAE Systems. During the quarter, we initiated new positions in RTX (Raytheon), Capital One and Somnigroup. In addition to Insmed and BAE, we also added to L3Harris, a global aerospace and defense company.
Read More
Calls of the Day: Wynn, Cummins, Boston Scientific, Applovin and Monster Beverage
Published: January 26, 2026 by: CNBC Television
Sentiment: Neutral
The Investment Committee debate the latest Calls of the Day.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: January 26, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
Penumbra Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Penumbra, Inc. - PEN
Published: January 16, 2026 by: PRNewsWire
Sentiment: Neutral
NEW YORK and NEW ORLEANS, Jan. 16, 2026 /PRNewswire/ -- Former Attorney General of Louisiana Charles C. Foti, Jr., Esq.
Read More
Down 6.3% in 4 Weeks, Here's Why Boston Scientific (BSX) Looks Ripe for a Turnaround
Published: January 16, 2026 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific (BSX) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Read More
How Low Can Boston Scientific Stock Go When Markets Turn Sour?
Published: January 16, 2026 by: Forbes
Sentiment: Negative
Boston Scientific (BSX) shares have decreased by 8.5% over the past 5 trading days. This recent drop highlights revived worries regarding the initial earnings dilution stemming from its Penumbra acquisition, yet such significant declines often raise a challenging question: is this weakness transitory, or does it indicate more profound issues within the company?
Read More
Boston Scientific Corporation (BSX) M&A Call Transcript
Published: January 15, 2026 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (BSX) M&A Call Transcript
Read More
Boston Scientific to acquire Penumbra in $14.5B deal
Published: January 15, 2026 by: Proactive Investors
Sentiment: Positive
Boston Scientific Corp (NYSE:BSX, XETRA:BSX) announced a definitive agreement to acquire medical device company Penumbra (NYSE:PEN) in a cash and stock transaction valuing Penumbra at $374 per share, or approximately $14.5 billion in enterprise value. Penumbra shares rose almost 12% on the news to about $350, while Boston Scientific shares fell 4.5% to about $90.
Read More
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Penumbra, Inc. (NYSE – PEN), Calavo Growers, Inc. (Nasdaq – CVGW), Clearwater Analytics Holdings, Inc. (NYSE - CWAN)
Published: January 15, 2026 by: GlobeNewsWire
Sentiment: Neutral
BALA CYNWYD, Pa., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no cost or financial obligation to you.
Read More
BSX Stock May Gain From Newly Inked Deal to Buy Valencia Technologies
Published: January 15, 2026 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific stock may rebound after agreeing to buy Valencia Technologies, adding the FDA-approved eCoin ITNS device to expand its Urology portfolio.
Read More
Boston Scientific to buy Penumbra in $14.5B deal to expand cardiovascular reach
Published: January 15, 2026 by: Invezz
Sentiment: Positive
Boston Scientific on Thursday announced plans to acquire Penumbra, a US-based thrombectomy specialist, in a cash-and-stock deal valued at about $14.5 billion, marking one of the largest transactions in the global medical technology sector this year.
Read More
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Published: January 13, 2026 by: Seeking Alpha
Sentiment: Neutral
Boston Scientific Corporation (BSX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Read More
3 MedTech Stocks Benefiting From Favorable Product Mix Shifts
Published: January 13, 2026 by: Zacks Investment Research
Sentiment: Positive
ANGO, BSX and MDT are showing earnings quality improve as higher-margin products take share, supporting margins and durable growth across MedTech.
Read More
PAHC vs. BSX: Which Stock Should Value Investors Buy Now?
Published: January 09, 2026 by: Zacks Investment Research
Sentiment: Positive
Investors looking for stocks in the Medical - Products sector might want to consider either Phibro Animal Health (PAHC) or Boston Scientific (BSX). But which of these two companies is the best option for those looking for undervalued stocks?
Read More
Is Boston Scientific Stock a Smart Pick for Your Portfolio Right Now?
Published: January 08, 2026 by: Zacks Investment Research
Sentiment: Positive
BSX is seeing solid international growth, MedSurg market-share gains and surging WATCHMAN sales, though macro and competition remain risks.
Read More
Boston Scientific (BSX) Just Overtook the 50-Day Moving Average
Published: January 07, 2026 by: Zacks Investment Research
Sentiment: Positive
After reaching an important support level, Boston Scientific (BSX) could be a good stock pick from a technical perspective. BSX surpassed resistance at the 50-day moving average, suggesting a short-term bullish trend.
Read More
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Published: December 30, 2025 by: Zacks Investment Research
Sentiment: Positive
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Read More
Boston Scientific's Global Expansion: What's Behind the Growth?
Published: December 18, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX expands globally with R&D, AI-driven manufacturing and Emerging Markets, aiming for $1B+ revenues in China in 2025.
Read More
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
Published: December 17, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
Read More
Here's Why Boston Scientific (BSX) is a Strong Growth Stock
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
Read More
PAHC vs. BSX: Which Stock Is the Better Value Option?
Published: December 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors with an interest in Medical - Products stocks have likely encountered both Phibro Animal Health (PAHC) and Boston Scientific (BSX). But which of these two stocks presents investors with the better value opportunity right now?
Read More
About Boston Scientific Corporation (BSX)
- IPO Date 1992-05-19
- Website https://www.bostonscientific.com
- Industry Medical - Devices
- CEO Michael F. Mahoney
- Employees 53000